A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder
Status:
Terminated
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and
pharmacokinetics of alprazolam extended release (XR) for the treatment of adolescents with
panic disorder
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.